Otsuka, Bristol-Myers ABILIFY approved as adjunct treatment in Bipolar I Disorder
Discovered by Otsuka and jointly developed and commercialized by Otsuka and Bristol-Myers, ABILIFY is the first and only available dopamine partial agonist and is indicated for the acute
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.